The estimated Net Worth of Arch Management Iv, L.L.C.J... is at least $6.71 Миллион dollars as of 19 February 2014. Arch J owns over 103,500 units of Concert Pharmaceuticals Inc stock worth over $6,710,447 and over the last 11 years Arch sold CNCE stock worth over $0.
Arch has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Arch bought 103,500 units of CNCE stock worth $1,449,000 on 19 February 2014.
The largest trade Arch's ever made was buying 103,500 units of Concert Pharmaceuticals Inc stock on 19 February 2014 worth over $1,449,000. On average, Arch trades about 103,500 units every 0 days since 2014. As of 19 February 2014 Arch still owns at least 801,726 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Arch J stock trades at the bottom of the page.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... и Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: